dimarts, 17 de novembre del 2015

MassDevice.com +3 | The top 3 medtech stories for November 17, 2015

plus3-1x1

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

 

3. Medtronic wins FDA nod for app-based remote pacer monitor

MassDevice.com news

Medtronic said today it won FDA premarket approval for its app-based MyCareLink Smart Monitor remote monitoring system for patients with implanted pacemakers.

The Fridley, Minn.-based medical giant said the newly-cleared monitoring system is the world’s 1st app-based pacemaker remote monitor. The system allows patients to transmit data from their Medtronic pacers to physicians who can analyze the data to make treatment decisions. Read more


2. FDA closes out AngioDynamics NanoKnife warning letter

MassDevice.com news

AngioDynamics said today it received a notice from the FDA closing out a warning letter it received in January 2011 in relation to its NanoKnife system.

The Albany, N.Y.-based company’s NanoKnife system uses high-voltage, low-energy electrical pulses which AngioDynamics said can permanently open pores in cell membranes. Read more


1. Ablative Solutions raises $2.4m, looks for $4m more

MassDevice.com news

Ablative Solutions has pulled in $2.4 million in a new round of financing, looking to raise another $4 million in the round, according to an SEC filing posted last week.

The Kalamazoo, Mich.-based company developed and produces the Peregrine infusion ablation catheter for treating hypertension. The Peregrine system infuses neurolytic agents into the perivascular space surrounding the renal artery to ablate the sympathetic nerves that contribute to hypertension. Read more

The post MassDevice.com +3 | The top 3 medtech stories for November 17, 2015 appeared first on MassDevice.



from MassDevice http://ift.tt/1SAWKVi

Cap comentari:

Publica un comentari a l'entrada